Edition:
United Kingdom

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

122.99USD
11 Dec 2018
Change (% chg)

$0.21 (+0.17%)
Prev Close
$122.78
Open
$124.15
Day's High
$124.15
Day's Low
$120.66
Volume
59,027
Avg. Vol
137,173
52-wk High
$179.65
52-wk Low
$105.22

Latest Key Developments (Source: Significant Developments)

GW Pharmaceuticals PLC Reports Fiscal Fourth Quarter Results
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC REPORTS FISCAL FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.GW PHARMACEUTICALS PLC - QTRLY LOSS PER SHARE $0.23.GW PHARMACEUTICALS PLC QTRLY TOTAL REVENUES $2.4 MILLION VERSUS $2.5 MILLION.GW PHARMACEUTICALS PLC - CASH AND CASH EQUIVALENTS AT SEPTEMBER 30, 2018 WERE $354.9 MILLION COMPARED TO $322.2 MILLION AS OF SEPTEMBER 30, 2017.  Full Article

GW Pharma Says DEA Has Rescheduled Epidiolex Oral Solution To Schedule V
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC AND ITS U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCE THE DEA HAS RESCHEDULED EPIDIOLEX® (CANNABIDIOL) ORAL SOLUTION TO SCHEDULE V.GW PHARMACEUTICALS PLC - WITH DEA DECISION, PRODUCT LABEL FOR EPIDIOLEX WILL BE FINALIZED.GW PHARMACEUTICALS PLC - ANTICIPATES MAKING EPIDIOLEX AVAILABLE WITHIN NEXT SIX WEEKS.GW PHARMACEUTICALS PLC - MEDICINE WILL BE MARKETED IN UNITED STATES BY GREENWICH BIOSCIENCES.  Full Article

GW Pharmaceuticals Reports Fiscal Q3 Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - GW Pharmaceuticals PLC ::GW PHARMACEUTICALS PLC REPORTS FISCAL THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS.  Full Article

FDA Approves Epidiolex (Cannabidiol) Oral Solution To Treat Rare, Severe Forms Of Epilepsy
Monday, 25 Jun 2018 

June 25 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION FOR TREATMENT OF SEIZURES ASSOCIATED WITH 2 SEVERE FORMS OF EPILEPSY IN PATIENTS 2 YRS & OLDER.U.S. FDA - FDA GRANTED APPROVAL OF EPIDIOLEX TO GW RESEARCH LTD.U.S. FDA - EPIDIOLEX APPROVED FOR TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME & DRAVET SYNDROME IN PATIENTS 2 YRS & OLDER.  Full Article

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - GW Pharmaceuticals Plc ::GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S..GW PHARMACEUTICALS - NOW REACQUIRED FULL OWNERSHIP OF DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT IN U.S. WITHOUT UPFRONT PAYMENT TO OTSUKA​.GW PHARMACEUTICALS - ‍AGREED TO MAKE CONTINGENT MILESTONE PAYMENTS TO OTSUKA, FIRST OF WHICH WOULD BECOME DUE UPON FDA APPROVAL OF SATIVEX​.GW PHARMACEUTICALS PLC - ‍TERMINATION OF PREVIOUS LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO IN RELATION TO SATIVEX IN U.S.​.  Full Article

GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Gw Pharmaceuticals Plc ::GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.GW PHARMACEUTICALS PLC - INTENDS TO SELL $225 MILLION OF AMERICAN DEPOSITARY SHARES.  Full Article

Evidence thin on medical pot, EU illegal drugs body says

LISBON, Dec 4 Evidence is still thin on the benefits of medicinal use of cannabis, an EU agency that monitors illegal drugs and addiction said on Tuesday, urging more study into the topic as growing numbers of countries allow it.